Compare TBI & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TBI | ACOG |
|---|---|---|
| Founded | 1985 | 2000 |
| Country | United States | Canada |
| Employees | N/A | 57 |
| Industry | Professional Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.9M | 110.4M |
| IPO Year | 1995 | N/A |
| Metric | TBI | ACOG |
|---|---|---|
| Price | $4.59 | $6.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 305.8K | 75.2K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.39 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.25 | $139.22 |
| Revenue Next Year | $3.90 | $134.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.18 | $4.50 |
| 52 Week High | $7.78 | $10.88 |
| Indicator | TBI | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 65.84 | 64.25 |
| Support Level | $4.57 | $6.46 |
| Resistance Level | $5.56 | $7.69 |
| Average True Range (ATR) | 0.29 | 0.57 |
| MACD | 0.12 | 0.07 |
| Stochastic Oscillator | 93.24 | 68.60 |
TrueBlue Inc is a provider of specialized workforce solutions that connect employers with talent. Its reportable segments include PeopleReady, which provides blue-collar contingent staffing and delivers on-demand and skilled labor across industries such as construction, transportation, retail, hospitality, and energy. The PeopleManagement segment offers contingent labor and outsourced industrial workforce solutions, mainly on-site at client facilities, through its OnSite and Centerline operations, focusing on workforce management and commercial driver services. PeopleSolutions delivers services focused on professional and specialized talent acquisition, as well as workforce management and compliance. The company generates the majority of its revenue from the PeopleReady segment.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.